News

Liverpool, April 2026 - At the Diabetes UK Professional Conference (DUK) 2026 last week, our partners at the Hummingbird Centre, Royal Glamorgan Hospital (Cwm Taf Morgannwg University Health Board, CTMUHB) presented the first interim results from their CloudCare pilot — the first deployment of CloudCare in the United Kingdom.

Background

CTMUHB serves one of the most socioeconomically deprived populations in Wales. Because access to innovative diabetes technology tends to be lower in such communities, the Health Board has committed to implementing the NICE TA 943 guidance on hybrid closed loop (HCL) systems. At the Hummingbird Centre, 54% (432 people) of the adult type 1 diabetes population currently uses an HCL system. To deliver this level of care sustainably, the team launched a 12-month CloudCare pilot in July 2025, enrolling 374 participants.

What is CloudCare

CloudCare ingests glucose data daily from any continuous or flash glucose monitoring system and is compatible with all HCL devices. Data is centrally triaged against criteria pre-agreed with the RGH diabetes team, so that only patients whose data indicates a need for action are escalated to the care team for review. Patients themselves receive a visual summary of their data through the CloudCare app, supporting self-management.

Six-month results

Complete glycaemic datasets were available for 142 participants at the analysis point. Within this group, a statistically significant improvement in eGMI was observed, with an average reduction of 4.7 mmol/mol (from 58.8 to 54.1 mmol/mol; p=0.009). The 2% increase in Time in Range did not reach statistical significance (p=0.064).

The most substantial gain was in capacity: the frequency of in-person clinic visits was reduced by more than 60% (p<0.0001). This finding is consistent with previously published Dutch data (van Beers CAJ et al., BMC Endocr Disord. 2025;25(1):88) and supports the reproducibility of the model outside the Netherlands.

Next steps

The remaining KPIs — including PROMs, PREMs, acute diabetes-related admissions, and HCP contact frequency — will be assessed at baseline and at 12 months. The final analysis is expected in late-2026.

Value Based Healthcare

These interim results align with the core principle of Value Based Healthcare: maintaining or improving outcomes without increasing cost, or reducing cost without compromising outcomes. The 12-month analysis will determine whether these early gains are sustained and in line with our results in the Netherlands.